Table 2.
Characteristics of the studies includes.
| Study (Year) [Reference] Acronym |
BC Stage Treatment Timing |
Groups Sample Size |
Age | WHO PA Guidelines Supervised or Home-Based | F Ses/ Wk |
I | T Min/ Ses |
T | D | Outcome Measures | PRO Measure Instrument |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adams (2016) [25] START |
I–III a (During CT) |
N = 200 AE = 64 RE = 66 UC = 70 |
48.8 (25–78) |
🗹 AE 🗹 RE |
|
3 | Moderate- vigorous 60–80% VO2 peak 2 × 8–12 reps (9 exercises) 60–70% 1RM |
60′ |
|
17 (9–24) |
QoL, Fatigue |
FACT-Na, TOI-An subscale, Fatigue subscale |
| Ammitzboll (2019) [26] LYCA |
I–III (CT, RT, HT; First year after BC surgery) |
N = 158 RE = 82 UC = 76 |
53 (33–73) 52 (30–74) |
🗹 RE |
|
3 | Low-moderate 3 × 8–12 reps (6 exercises) |
50–55′ |
|
52 | HRQoL, Fatigue |
EORTC QLQ C30, FACIT, EORTC C30, subscales |
| Baglia (2019) [27] HOPE |
I–III (CT/RT) |
N = 121 Exc = 61 UC = 60 |
62.0 (7.0) 60.5 (7.0) |
🗹 AE + RE |
|
3-5 (AE) 2 (RE) |
50–80% HRmax | 150′ (AE) |
|
12 | QoL, Fatigue |
FACT, FACT-G, FACT-B, SF-36, FACIT-Fatigue |
| Basen- Engquist (2020) [28] |
II–III (CT/ RT—during CT treatment) |
N = 37 Exp = 19 UC = 18 |
49.6 (13.3) 49.2 (9.2) |
🗹 RE + Flexibility exercises |
|
3 | Moderate | 60′ |
|
13 | QoL, Body Image |
SF-36, BIS |
| Bloomquist (2019) [29] | I–III (CT—during treatment) |
N = 153 Exc = 75 Con = 78 |
51.5 (9.6) 52.0 (9.3) |
🗹 HIGH RE + AE 🗵 Con = AE |
|
3 | 70–90% 1 RM (RE) 85–90% HRmax (HIIT) Low-intensity (target = 10,000 steps) |
90–120′ |
|
12 | QoL | EORTC QLQ- BR23 |
| Cadmus (2009) [30] IMPACT |
0–III a (CH/RT/HT—during treatment) |
N = 50 Exc = 25 UC = 25 |
54.5 (8.2) 54.0 (10.9) |
🗹 AE |
|
5 | Moderate-vigorous (60–80% HRmax) | 30′ |
|
24 | Happiness depression anxiety, stress, self-esteem, QoL |
HM CES-D STAI, 10-PSS Rosenberg S-ES, FACT-B SF-36 |
| Cadmus (2009) [31] YES |
0–III a (CH/RT/HT—Post-treatment, 6-moth follow-up) |
N = 75 Exc = 37 UC = 38 |
56.5 (9.5) 55.1 (7.7) |
🗹 AE |
|
5 | Modrate-vigorous (60–80% HRmax) | 30′ |
|
24 | Happines, Depression, Anxiety, Stress, Self-esteem, QoL |
HM, CES-D, STAI-YI, 10-PSS, Rosenberg S-ES, FACT-B SF-36 |
| Campbell (2005) [31] | I–II (CT/RT—during treatment) |
N =22 Exc = 12 UC = 10 |
48 (10) 47 (5) |
🗵 AE + RE |
|
2 | 60–75% HRmax | 20′ |
|
12 | Fatigue QoL |
FACT-G FACT-B SWLS, PFS |
| Cantarero-Villanueva (2011) [32] CUIDATE |
I–III A (CT/RT—Post-treatment) |
N = 67 Exc = 32 UC = 35 |
49 (9) 48 (9) |
🗵 Multimodal intervention |
|
3 | Low-intensity | 90′ | - | 8 | Fatigue | PFS |
| Cantarero-Villanueva (2013) [33] | I–III A (CT/RT—Post-treatment) |
N = 61 Exc = 32 UC= 29 |
49 (7) 47 (8) |
🗹 AE + RE (deep pool) |
|
3 | 60–75% HRmax | 60′ |
|
8 | Fatigue Mood state |
PFS Profile of Mood States (Spanish version) |
| Carayol (2019) [34] APAD1 |
I–III c (CT/RT—during treatment) |
N = 143 Exc = 72 UC = 71 |
51.2 (10.9) 52.1 (9.3) |
🗵 RE + AE + nutritional therapeutic education sessions |
|
2 (AE) 1 (RE) |
Moderate (AE) 50–75% HRmax |
30–45′ |
|
26′ | Fatigue QoL Anxiety Depression |
MFI, EORTC QLQ-C30 HADS |
| Casla (2015) [35] | I–III (CT/RT—post-treatment) |
N = 94 Exc = 47 UC = 47 |
45.91 (8.21) 51.87 (8.21) |
🗹 AE + RE |
|
3 | Progresive 55–85% HRR (AE) 10–20 Borg Scale (RE) |
60′ |
|
12 | QoL | SF-36 |
| Cormie (2013) [36] | I–III (CT/RT/HT—timing not reported) |
N = 62 Exc HL = 22 Exc LL = 21 UC= 19 |
56.1 (8.1) 57.0 (10.0) 58.6 (6.7) |
🗹 RE HL = High-load 🗹 RE LL = Low-load |
|
2 | Moderate-high 12–16 Borg scale [RPE] RE HL (10–6 reps, 75–85% 1RM); RE LL (20–15 reps, 55–65% 1RM) |
60′ |
|
12 | QoL | QLQ-BR23 SF-36 |
| Cornette (2016) [37] SAPA |
I–III b (CT/RT—during treatment) |
N = 42 Exc = 20 UC = 22 |
52 (37–73) 49 (37–68) |
🗵 AE (APA) + RE |
|
2 (AE) 1 (RE) |
60 cycling revolutions/min or HR RE (2 sets of 8–12 reps of 5 exercises) |
25-45′ |
|
27 | QoL, Fatigue, Anxiety and Depression |
MFI-20, EORTC QLQ-C30, HADS |
| Courneya (2003) [38] | I–III a (CH/RT/HT—post-treatment) |
N = 52 Exc = 24 UC = 28 |
59 (5) 58 (6) |
🗵 AE |
|
3 | 70–75% VO2 max | 35′ |
|
15 | QoL, Well-being, Happiness, Self-Esteem, Fatigue |
FACT-B, FACT-G, HM, Rosenberg S-ES, FACT-F |
| Courneya (2007) [39] | I–III a (CT—during adjuvant CT) |
N = 242 Exc AE = 78 Exc RE = 82 UC = 82 |
49.2 (25–78) 49.0 (30–75) 49.5 (25–76) 49.0 (26–78) |
🗵 AE RE |
|
3 | 60–80% VO2 max 60–70% 1RM |
15–45′ |
|
17 (9–24) | Fatigue, Self-Esteem, Depression, Anxiety |
FACT-A, Rosenberg S-ES, CES-D, Spielberger SAI |
| Daley (2007) [40] | Stage not reported (CT/RT/HT—post-treatment) |
N = 108 Exc = 34 Exc PE = 36 UC = 38 |
51.6 (8.8) 50.6 (8.7) 51.1 (8.6) |
🗹 AE |
|
3 | Moderate- intensity (65–85% HRmax and 12–13 RPE) Placebo Exercise (light-intensity 40% HRmax) |
50′ |
|
8 | QoL, Fatigue, Depression |
FACT-G, FACTB, PFS, BDI-II |
| Dieli (2018) [41] | 0–III (CT/RT— post-treatment) |
N = 91 Exc = 46 UC = 45) |
53.5 (10.4) |
🗹 AE + RE |
|
3 | Moderate-vigorous (65–85% HRmax) 
|
50′ (AE) |
|
16 | QoL, Fatigue, Depression |
FACT-B, SF-36, BFI, CES-D |
| Dong (2019) [42] CEIBISMS |
I–III (CT/RT—post-treatment) |
N = 50 Exc = 26 UC = 24 |
48.00 (5.54) 51.63 (7.49) |
🗹 (Internet and social media app) AE + RE |
|
4 (AE) 3 (RE) |
not reported (RPE) | 30′ |
|
12 | QoL | SF-36 |
| Ergun (2013) [43] |
I–III A (CT/RT/mastectomy, axillary dissection and sentinel lymph node biopsy—post-treatment) |
N = 60 Exp (1) = 20 Exp (2) = 20 UC = 20 |
49.65 (8.25) 55.05 (6.85) 55.30 (10.37) |
🗹 AE + RE + Brisk walk 🗵 Brisk walk |
|
3 + 3 3 |
Moderate | 45′ + 30′ 30′ |
|
12 | QoL, Fatigue, Depression |
EORTC QLQ-C30, BFI, BDI |
| Fernández-Lao (2013) [44] | I–III a (CT/RT/HT post-CT treatment) |
N = 98 Exc L = 31 Exc W = 33 UC = 34 |
49 (8) 48 (7) 48 (8) |
Multimodal (AE + RE) 🗹 Exp L = Land 🗹 Exp W = Water |
|
3 | 60% HRmax | 60′ |
|
8 | QoL, Body image | EORTC QLQ-BR23 |
| Fillion (2008) [45] | 0–III (RT + CT/HT—post-treatment) |
N = 87 Exc = 44 UC = 43 |
53.09 (9.65) 51.84 (10.25) |
🗹 AE + Psycho-educative and fatigue management sessions |
|
3–5 | 65–75% HRmax | 20–30′ |
|
10 | Fatigue, Energy level, QoL, Emotional distress |
MFI, Vigor-POMS, SF-12, POMS anxiety + depression |
| Galiano-Castillo (2016) [46] e-CUIDATE |
0–III (CT/RT—adjuvant therapy/except HT) |
N = 81 Exc = 40 UC = 41 |
47.4 (9.6) 49.2 (7.9) |
🗹 AE + RE Internet-based |
|
3 | Moderate | 90′ |
|
8 | QoL, Fatigue, Body image |
EORTC QLQ-C30, R-PFS |
| Ghavami and Akyolcu (2017) [47] | I–III (CT/RT— Post-treatment) |
N = 80 Exc (N = 40) UC = 40 |
48.75 (9.49) 49.23 (9.46) |
🗹 AE Life-style intervention (dietary energy-restriction) |
|
3–5 | 70–85% HRR | 45–60′ |
|
24 | Fatigue, Quality of sleep, QoL |
CFS, PSQI, EORTC QLQ-C30, QLQ-BR23 |
| Gokal (2016) [48] | I–III (CT—during CT treatment) |
N = 50 Exc = 25 UC = 25 |
52 (11.7) 52 (8.9) |
🗹 AE |
|
5 | Moderate (brisk walking) |
10–30′ |
|
12 | Anxiety, Depression, Fatigue, Self-esteem, Mood |
HADS, FACT-F Rosenberg S-ES, POMS-SF |
| Hagstrom (2016) [49] | I–III a (CT/RT/HT—post- CT/ treatment) |
N = 39 Exc = 20 UC =19 |
51.2 (8.5) 52.7 (9.4) |
🗹 RE |
|
3 | 8RM (VPA) (3 sets of 8–10 reps of 6 full body exercises) |
60′ |
|
16 | QoL, Fatigue |
FACIT-F, FACT-G |
| Harvie (2019) [50] | Early stage (CT/RT/HT —during CT treatment |
N = 409 Exc C = 137 Exc H =134 UC =138 |
54.0 (9.2) 54.6 (11.2) 55.3 (10.5) |
🗹 Exp C = Community Exp H = Home (phone and mail programme) |
|
5 (AE) 2 (RE) |
Moderate (50–80% HRmax) | 30′ (AE) + 10′ (RE) |
|
52 | Fatigue | FACT-TOI |
| Hayes (2013) [51] Exercise for Health |
0–III (CT/RT/HT—Pre, during and/or post- intervention) |
N = 194 Exc FtF = 67 Exc Tel = 67 UC = 60 |
51.2 (8.8) 52.2 (8.6) 53.9 (7.7) |
🗹 Exp FtF = (Face-to-face) AE + RE 🗹 Exp Tel = (Telephone) AE + RE |
|
≥4 (AE) ≥2 (RE) |
Low-moderate to moderate-high
|
≥45′ |
|
24 | QoL, Fatigue, Anxiety, Depression |
FACT-B + 4, FACIT-F |
| Herrero (2006) [52] | I–II of ductal brest carcinoma (CT/RT— Post-treatment) |
N = 16 Exc = 8 UC = 8 |
50 (5) 51(10) |
🗹 AE + RE |
|
3 | 70–80% HRmax (AE) 12–15 to 8–10RM (RE)
|
90′ |
|
8 | QoL | EORTC QLQ-C30, |
| Huang (2019) [53] | I-III (CT/ RT/ HT – scheduled for adjuvant CT |
N= 159 Exc= 81 UC= 78 |
48.32 (7.90) 48.31 (8.65) |
🗹 AE |
|
3–5 | 30–70% HRR | 12–25′ to 35–40′ |
|
12 | Anxiety and Depression |
BFI, HADS-A, HADS-D, PSQI |
| Hwang (2008) [54] | Early stage (RT—waiting list for RT) |
N = 40 Exc = 17 UC = 23 |
46.3 (7.5) 46.3 (9.5) |
🗹 AE + RE Con = self-shoulder stretching exercise |
|
3 | 50–70% HRmax | 50′ |
|
5 | QoL, Fatigue |
WHOQOL-BREF, BFI |
| Ligibel (2016) [55] | Metastatic BC (endocrine therapy vs. CT/biologic therapy—during treatment) |
N = 98 Exc = 47 UC = 51 |
49.3 (9.6) 50.7 (9.4) |
🗹 AE |
|
Not reported | Moderate | 150′ /wk |
|
16 | QOL, Fatigue |
EORTC QLQ C-30, HADS, FACIT-F |
| Mijwel (2019) [56] OptiTrain |
I–III a (CT—during adjuvant CT treatment) |
N = 206 Exc AE = 72 Exc RE = 74 UC =60 |
54.4 (10.3) 52.7 (10.3) 52.6 (10.2) |
🗵 AE-HIIT 🗵 RE-HIIT |
|
2 | Moderate (AE) High, 70–80% 1RM (RE) |
60′ |
|
16 | Fatigue, QoL, Distress |
PFS, EORTC-QLQ-C30, MSAS |
| Milne (2008) [57] |
Early stage (CT/RT—Post-treatment w or w/o HT |
N = 58 Exc = 29 UC = 29 |
55.2 (8.4) 55.1 (8.0) |
🗵 AE + RE + stretching |
|
3 | (about) 75% HRmax |
30′ |
|
12 | QoL, Fatigue, Anxiety |
FACT-B, SCFS, SPAS-7 |
| Murtezani (2014) [58] | Early stage (CT/RT—Post-treatment w or w/o HT) |
N = 62 Exp = 30 UC = 32 |
53 (11) 51 (11) |
🗵 AE |
|
3 | 50–75% HRR | 25–45′ |
|
10 | QoL | FACT‑B, FACT-G |
| Musanti (2012) [59] | I–III b (CT/RT— Post-treatment w or w/o HT) |
N = 42 Exp AE = 10 Exp RE = 9 Exp AR = 11 Con F = 12 |
51 (5.5) 52 (8.9) 48 (6.7) 52 (7.9) |
🗵 AE 🗹 RE 🗹 AE + RE |
|
3 3 4–5 (AE) 2 (RE) |
40–65% to 85% HRmax 3–5 to 7–8 RPE (0–10 scale) |
15–30′ |
|
12 | Fatigue, Anxiety, Depression, Self-esteem |
PFS, HADS, Rosenberg S-ES |
| Mutrie (2007) [60] |
0–III (CT/RT/combined—during and/or post-treatment) |
N = 174 Exp = 82 UC = 92 |
51.3 (10.3) 51.8 (8.7) |
🗵 AE + RE |
|
2 | 50–75% HRmax | 45′ |
|
12 | QoL, Depression |
FACT-G, FACT-B, FACT-F, PANAS, SPAQ, BDI |
| Naraphong (2015) [61] | I–III a (during CT treatment) |
N = 23 Exp = 11 UC = 12 |
46.36 (9.37) 47.17 (6.87) |
🗹 AE |
|
3–5 | Low-moderate (40–60% HRmax) weekly increase of 5% of average past week steps
|
30–40′ |
|
10 | Fatigue, Sleep disturbance, Symptom distress |
PFS-R, GSD, POMS-BF, MSAS |
| Ohira (2006) [62] WTBS |
I–III, DCIS (CT/RT/HT |
N = 79 Exp = 39 UC = 40 |
53.3 (8.7) 52.8 (7.6) |
🗹 RE |
|
2 | 10 max/reps | 60′ |
|
24 | QoL, Depression |
CARES-SF, CES-D |
| Paulo (2019) [63] | I–III (CT/RT—undergoing aromatase inhibitor therapy) |
N = 36 Exp = 18 UC = 18 |
63.2 (7.1) 66.6 (9.6) |
🗹 AE + RE UC = Stretching |
|
3 2 |
60–85% HRmax (AE) 15 reps or 65% of max. reps to 8 reps or 80% of max. reps (RE) |
30′ (AE) 40′ (RE) 45′ |
|
36′ | QoL | SF36, EORTC QLQ-C30, EORTC QLQ-BR23 |
| Pinto (2005) [64] | 0–II (CT/RT—post CT treatment) |
N = 82 Exp = 39 UC = 43 |
53.42 (9.08) 52.86 (10.38) |
🗹 AE |
|
2–5 | 55–65% HRmax
|
10–30′ |
|
12 | Anxiety and depression, Fatigue |
POMS, LASF |
| Reis (2018) [65] | I–IV (CT/RT—during CT/RT treatment) |
N = 28 Exp =14 UC =14 |
47.64 (7.60) 45.79 (8.1) |
🗹 AE + RE + Flexibility |
|
3 (AE + RE) 2 (Flex) |
50–60%/80–90% target HR (AE) 3 sets of 12 reps of 12 maximum repetition (RE) |
30′ (AE) 30′ (RE) 15′ |
|
12 | Fatigue | PFS-R |
| Rogers (2015) [66] | I–II BC (CT/RT/HT- DCIS) |
N = 44 Exp = 20 UC = 24 |
57.2 ± 5.5 (45–69) 55.2 ± 9.1 (32–67) |
🗹 AE + RE |
|
4 (AE) 2 (RE) |
Moderate (48–52% HRR) |
9–40′ |
|
10 | Fatigue, Sleep dysfunction, Anxiety, Depression |
FSI, fatigue interference, PROMIS |
| Rogers (2017) [67] BEAT Cancer |
I–III A (CT/RT/HT-DCIS) |
N = 222 Exp = 110 UC = 112 |
54.4 (8.5) | 🗹 AE |
|
≥3 | Moderate (40–59% HRR)
|
≥60′ |
|
10 | Fatigue, Anxiety, Depression |
FSI, HAD |
| Saarto (2012) [68] |
Early stage (CT/RT) |
N = 500 Exp = 263 UC = 237 |
52.3 (36–68) 52.4 (35–68) |
🗹 AE |
|
1 2–3 |
5–7 METs | 60′ |
|
48 | QoL, Fatigue, Depression, Body image |
EORTC QLQ-C30, BR-23, FACIT-F, RBDI, WHQ |
| Saxton (2014) [69] | Early stage (post- treatment) |
N = 85 Exp (N = 44) UC =41 |
55.8 (10.0) 55.3 (8.8) |
🗹 AE + RE (+ education about hypocaloric diet intake) |
|
3 | 65–85% HRmax | 40–45′ |
|
24 | Depression, Stress |
BDI-II, PSS |
| Schmidt (2012) [70] | I–III (CT/RT—Post-treatment) |
N = 33 Exp =15 UC =18 |
58 (8.41) 55 (10.59) |
🗵 RE |
|
1 | 50% h 1RM | 60′ |
|
26 | QoL | EORTC QLQ C30, BR23 |
| Schmidt (2015) [71] BEATE |
Tumor stage 1–4 (CH, HT etc.—during CT treatment |
N = 95 Exp = 49 UC = 46 |
52.2 (9.9) 53.3 (10.2) |
🗵 RE |
|
2 | 60–80% 1RM | 60′ |
|
12 | Fatigue, QoL, Depression |
FAQ, EORTC QLQ C30 + BR23, CES-D |
| Schmidt (2015b) [72] | Primary moderate- or high-risk BC (CT—during CT treatment) |
N = 67 Exp AE = 20 Exp RE = 21 UC = 26 |
56 (10.15) 53 (12.55) 54 (11.19) |
🗵AE 🗹 RE |
|
2 | 11–14 Borg scale (AE) 50% h 1RM (RE) |
60′ |
|
12 | QoL Fatigue, Body image |
EORTC QLQ C30 + BR23, MFI20 |
| Schmidt (2016) [73] BEST |
0–III (RT—During RT) |
N = 103 Exc = 54 UC = 49 |
57.1 (8.9) 57.3 (8.8) |
🗹 RE |
|
2 | 3 sets of 8–2 reps of 8 machine-based exercises | 60′ |
|
12 | Fatigue, QoL |
FAQ, QLQ-C30, CES-D |
| Scott (2013) [74] | I–III (CT/RT/HT—Post-treatment) |
N = 90 Exc = 47 UC = 43 |
55.6 (10.2) 55.9 (8.9) |
Lifestyle intervention 🗵 AE + RE + hypocaloric healthy eating program |
|
3 | 65–85% HRmax | 30′ (AE) 10–15′ (RE) |
|
24 | QoL | FACT-G, FACT-B |
| Segal (2001) [75] |
I–II (CH/RT HT—during treatment) |
N = 123 Exc S = 42 Exc SD = 40 UC = 41 |
51.0 (8.7) 51.4 (8.7) 50.3 (8.7) |
🗹 AE (S) Supervised 🗹 AE (SD) Self-directed |
|
5 3 |
50–60% VO2 max | 60′ |
|
26 | QoL | MOS SF-36, FACT-G, FACT-B |
| Shobeiri (2016) [76] | I–II (CT/RT—Post-treatment w or w/o HT) |
N = 60 Exc = 30 UC = 30 |
42.70 (9.6) 43.50 (8.60) |
🗵 AE |
|
2 | 50–75% HRR | 25–45′ |
|
10 | Fatigue, QoL, Body image |
EORTC QLQ-C30, EORTC QLQ-BR23 |
| Speack (2010) [77] PAL |
0–III, DCIS (CT/RT— Post-treatment) W or w/o lymphedema |
N = 234 Exc = 59 Exc wL = 54 UC = 63 UC wL = 58 |
55 (7) 58 (9) 57 (8) 58 (9) |
🗹 RE 🗹 RE wL * wL = with lymphedema |
|
2 | not reported | 90′ |
|
52 | Body image, QoL |
BIRS, SF-36 |
| Steindorf (2014) [78] BEST |
0–III (CT, RT, HT, trastuzumab therapy—during RT) |
N = 155 Exc = 77 UC = 78 |
55.2 (9.5) 56.4 (8.7) |
🗹 RE |
|
2 | 60–80% 1RM | 60′ |
|
12 | Fatigue, QoL, Depression, Body image |
FAQ, EORTC QLQ-C30, EORTC QLQ-C23, CES-D, |
| Travier (2015) [79] PACT |
M0 (CT—During; RT after intervention) |
N =164 Exc = 87 UC = 77 |
49.7 (8.2) 49.5 (7.9) |
🗹 AE + RE |
|
2 | Moderate- vigorous 65–75% to 45% 1RM (RE) HR ventilatory threshold (AE) |
60′ |
|
18 | Fatigue, QoL, Anxiety, Depression |
MFI, FQL, SF-36, QLQ-C30, HADS |
| Wang (2011) [80] | I–II (CT/RT—before CT treatment) |
N = 72 Exc = 35 UC = 37 |
48.40 (10.15) 52.3 (8.84) |
🗹 AE |
|
3–5 | 40–60% HRmax | ≥30′ |
|
6 | QoL, Fatigue, Sleep disturbances, |
FACT-G, FACIT-F, PSQI |
| Winters (2012) [81] POWIR |
I–III a (CT/RT—Post-treatment) |
N = 106 Exc = 52 UC = 54 |
62.3 (6.7) 62.6 (6.7) |
🗹 RE + impact training (POWIR) UC = Stretching placebo program. (Flexibility) |
|
2 | 60–80% 1RM | 60′ |
|
52 | Fatigue | SCF, SF-36 |
Frequency, Intensity, Time and Type (FITT); Duration (D); Patient Reported Outcome (PRO); Exercise intervention group (Exc); Usual care or control group (UC); Aerobic Exercise training (AE); Resistance Exercise training (RE); WHO guidelines of minimum physical activity/exercise recommended (🗹: accomplished; 🗵 not accomplished); Chemotherapy (CT); Radiotherapy (RT); Hormonal Therapy (HT); Quality of Life (QoL); ratings of perceived exertion (RPE); moderate to vigorous physical activity (MVPA); Heart Rate Reserve (HRR); Ductal Carcinoma in Situ (DCIS); PRO measures: Beck Depression Inventory (BDI); The Brief Fatigue Inventory (BFI); European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30); Finnish modified version of Beck’s 13-item depression scale (RBDI); Functional Assessment of Cancer Therapy, FACT-Anemia (FACT-A); Functional Assessment of Cancer Therapy-Anemia (FACT-An); Breast (FACT-B); Fatigue (FACT-F); General (FACT-G); Functional Assessment of Chronic Illness Therapy (FACIT); questionnaire for fatigue (FACIT-F); Medical Outcomes Study Short Form (MOS SF-36); Piper Fatigue Scale (PFS); Schwartz Cancer Fatigue Scale (SCF); Women’s Health Questionnaire (WHQ); Patient Reported Outcomes Measurement Information System (PROMIS); Body Image Scale (BIS); Happiness Measure (HM); Social Physique Anxiety Scale-7 items (SPAS-7); Memorial Symptom Assessment Scale (MSAS); Fatigue Assessment Questionnaire (FAQ); Hospital Anxiety and Depression Scale (HADS); HADS-Anxiety (HADS-A); HADS-Depression (HADS-D); Pittsburgh Sleep Quality Index (PSQI); Rosenberg Self-Esteem scale (S-ES); Center for Epidemiological Studies Depression Scale (CES-D); Spielberger State Anxiety Inventory (SAI); Physical Function scale (SF-36); World Health Organization Quality of Life-BREF (WHOQOL-BREF); State-Trait Anxiety Inventory, (STAI); STAI-State Anxiety (STAI-YI), Cohen’s 10-item Perceived Stress Scale (10-PSS); Trial Outcome Index-Anemia (TOI-An) subscale and fatigue subscale; Health Related Quality of Life (HRQoL); Profile of Mood States (POMS); Linear analog scale for fatigue (LASF); Cancer Rehabilitation Evaluation System-Short Form (CARES-SF); Body Image and Relationships Scale (BIRS). * Age presented with mean and SD or range where reported. Supervised intervention; Home-based intervention; Aerobic exercise; Resistance exercise/strength training; Flexibility/Stretching exercises; Progressive; Aerobic exercise (control).